Literature DB >> 11447196

Enhanced susceptibility to pulmonary infection with Burkholderia cepacia in Cftr(-/-) mice.

U Sajjan1, G Thanassoulis, V Cherapanov, A Lu, C Sjolin, B Steer, Y J Wu, O D Rotstein, G Kent, C McKerlie, J Forstner, G P Downey.   

Abstract

Progressive pulmonary infection is the dominant clinical feature of cystic fibrosis (CF), but the molecular basis for this susceptibility remains incompletely understood. To study this problem, we developed a model of chronic pneumonia by repeated instillation of a clinical isolate of Burkholderia cepacia (genomovar III, ET12 strain), an opportunistic gram-negative bacterium, from a case of CF into the lungs of Cftr (m1unc-/-) (Cftr(-/-)) and congenic Cftr(+/+) controls. Nine days after the last instillation, the CF transmembrane regulator knockout mice showed persistence of viable bacteria with chronic severe bronchopneumonia while wild-type mice remained healthy. The histopathological changes in the lungs of the susceptible Cftr(-/-) mice were characterized by infiltration of a mixed inflammatory-cell population into the peribronchiolar and perivascular spaces, Clara cell hyperplasia, mucus hypersecretion in airways, and exudation into alveolar airspaces by a mixed population of macrophages and neutrophils. An increased proportion of neutrophils was observed in bronchoalveolar lavage fluid from the Cftr(-/-) mice, which, despite an increased bacterial load, demonstrated minimal evidence of activation. Alveolar macrophages from Cftr(-/-) mice also demonstrated suboptimal activation. These observations suggest that the pulmonary host defenses are compromised in lungs from animals with CF, as manifested by increased susceptibility to bacterial infection and lung injury. This murine model of chronic pneumonia thus reflects, in part, the situation in human patients and may help elucidate the mechanisms leading to defective host defense in CF.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11447196      PMCID: PMC98610          DOI: 10.1128/IAI.69.8.5138-5150.2001

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  66 in total

1.  Cystic fibrosis lung inflammation: early, sustained, and severe.

Authors:  A Cantin
Journal:  Am J Respir Crit Care Med       Date:  1995-04       Impact factor: 21.405

2.  Lung disease in the cystic fibrosis mouse exposed to bacterial pathogens.

Authors:  D J Davidson; J R Dorin; G McLachlan; V Ranaldi; D Lamb; C Doherty; J Govan; D J Porteous
Journal:  Nat Genet       Date:  1995-04       Impact factor: 38.330

3.  Cyclic AMP signaling pathways are important in IL-1 beta transcriptional regulation.

Authors:  G Chandra; J P Cogswell; L R Miller; M M Godlevski; S W Stinnett; S L Noel; S H Kadwell; T A Kost; J G Gray
Journal:  J Immunol       Date:  1995-11-15       Impact factor: 5.422

4.  Early pulmonary inflammation in infants with cystic fibrosis.

Authors:  T Z Khan; J S Wagener; T Bost; J Martinez; F J Accurso; D W Riches
Journal:  Am J Respir Crit Care Med       Date:  1995-04       Impact factor: 21.405

5.  Transcriptional regulation of the intercellular adhesion molecule-1 gene by inflammatory cytokines in human endothelial cells. Essential roles of a variant NF-kappa B site and p65 homodimers.

Authors:  H C Ledebur; T P Parks
Journal:  J Biol Chem       Date:  1995-01-13       Impact factor: 5.157

6.  The emergence of a highly transmissible lineage of cbl+ Pseudomonas (Burkholderia) cepacia causing CF centre epidemics in North America and Britain.

Authors:  L Sun; R Z Jiang; S Steinbach; A Holmes; C Campanelli; J Forstner; U Sajjan; Y Tan; M Riley; R Goldstein
Journal:  Nat Med       Date:  1995-07       Impact factor: 53.440

7.  Role of mutant CFTR in hypersusceptibility of cystic fibrosis patients to lung infections.

Authors:  G B Pier; M Grout; T S Zaidi; J C Olsen; L G Johnson; J R Yankaskas; J B Goldberg
Journal:  Science       Date:  1996-01-05       Impact factor: 47.728

8.  A murine model of cystic fibrosis.

Authors:  J N Snouwaert; K K Brigman; A M Latour; E Iraj; U Schwab; M I Gilmour; B H Koller
Journal:  Am J Respir Crit Care Med       Date:  1995-03       Impact factor: 21.405

9.  Cable (cbl) type II pili of cystic fibrosis-associated Burkholderia (Pseudomonas) cepacia: nucleotide sequence of the cblA major subunit pilin gene and novel morphology of the assembled appendage fibers.

Authors:  U S Sajjan; L Sun; R Goldstein; J F Forstner
Journal:  J Bacteriol       Date:  1995-02       Impact factor: 3.490

10.  Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid.

Authors:  J J Smith; S M Travis; E P Greenberg; M J Welsh
Journal:  Cell       Date:  1996-04-19       Impact factor: 41.582

View more
  36 in total

1.  Abnormal expression of Muc5b in Cftr-null mice and in mammary tumors of MMTV-ras mice.

Authors:  Hélène Valque; Valérie Gouyer; Marie-Odile Husson; Frédéric Gottrand; Jean-Luc Desseyn
Journal:  Histochem Cell Biol       Date:  2011-10-18       Impact factor: 4.304

2.  Burkholderia cenocepacia creates an intramacrophage replication niche in zebrafish embryos, followed by bacterial dissemination and establishment of systemic infection.

Authors:  Annette C Vergunst; Annemarie H Meijer; Stephen A Renshaw; David O'Callaghan
Journal:  Infect Immun       Date:  2010-01-19       Impact factor: 3.441

3.  Immune Recognition of the Epidemic Cystic Fibrosis Pathogen Burkholderia dolosa.

Authors:  Damien Roux; Molly Weatherholt; Bradley Clark; Mihaela Gadjeva; Diane Renaud; David Scott; David Skurnik; Gregory P Priebe; Gerald Pier; Craig Gerard; Deborah R Yoder-Himes
Journal:  Infect Immun       Date:  2017-05-23       Impact factor: 3.441

4.  Response to acute lung infection with mucoid Pseudomonas aeruginosa in cystic fibrosis mice.

Authors:  Anna M van Heeckeren; Mark D Schluchter; Wei Xue; Pamela B Davis
Journal:  Am J Respir Crit Care Med       Date:  2005-11-04       Impact factor: 21.405

5.  Drosophila melanogaster as a model host for the Burkholderia cepacia complex.

Authors:  Josée Castonguay-Vanier; Ludovic Vial; Julien Tremblay; Eric Déziel
Journal:  PLoS One       Date:  2010-07-12       Impact factor: 3.240

Review 6.  The art of persistence-the secrets to Burkholderia chronic infections.

Authors:  Eric R G Lewis; Alfredo G Torres
Journal:  Pathog Dis       Date:  2016-07-19       Impact factor: 3.166

7.  Azithromycin increases survival and reduces lung inflammation in cystic fibrosis mice.

Authors:  Wan C Tsai; Marc B Hershenson; Ying Zhou; Umadevi Sajjan
Journal:  Inflamm Res       Date:  2009-03-07       Impact factor: 4.575

8.  Comparative analysis of plant and animal models for characterization of Burkholderia cepacia virulence.

Authors:  Steve P Bernier; Laura Silo-Suh; Donald E Woods; Dennis E Ohman; Pamela A Sokol
Journal:  Infect Immun       Date:  2003-09       Impact factor: 3.441

9.  Protection of Cftr knockout mice from acute lung infection by a helper-dependent adenoviral vector expressing Cftr in airway epithelia.

Authors:  David R Koehler; Umadevi Sajjan; Yu-Hua Chow; Bernard Martin; Geraldine Kent; A Keith Tanswell; Colin McKerlie; Janet F Forstner; Jim Hu
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-12       Impact factor: 11.205

10.  Cytosolic phospholipase A2-alpha is necessary for platelet-activating factor biosynthesis, efficient neutrophil-mediated bacterial killing, and the innate immune response to pulmonary infection: cPLA2-alpha does not regulate neutrophil NADPH oxidase activity.

Authors:  Barry B Rubin; Gregory P Downey; Adeline Koh; Norbert Degousee; Farideh Ghomashchi; Laxman Nallan; Eva Stefanski; Denis W Harkin; Chunxiang Sun; Brian P Smart; Thomas F Lindsay; Vera Cherepanov; Eric Vachon; David Kelvin; Martin Sadilek; Glenn E Brown; Michael B Yaffe; Jonathan Plumb; Sergio Grinstein; Michael Glogauer; Michael H Gelb
Journal:  J Biol Chem       Date:  2004-10-08       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.